Altamira Therapeutics Ltd. (NASDAQ:CYTO – Free Report) – Diamond Equity boosted their FY2024 earnings estimates for shares of Altamira Therapeutics in a research report issued to clients and investors on Wednesday, September 25th. Diamond Equity analyst H. Diamond now forecasts that the company will post earnings per share of ($2.65) for the year, up from their previous forecast of ($4.26). The consensus estimate for Altamira Therapeutics’ current full-year earnings is ($4.26) per share. Diamond Equity also issued estimates for Altamira Therapeutics’ FY2025 earnings at ($1.17) EPS.
Altamira Therapeutics Stock Performance
NASDAQ:CYTO opened at $0.63 on Monday. The business has a fifty day moving average price of $0.91 and a 200-day moving average price of $1.31. Altamira Therapeutics has a one year low of $0.60 and a one year high of $17.20.
About Altamira Therapeutics
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens.
Further Reading
- Five stocks we like better than Altamira Therapeutics
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Why Lennar Stock Could Be the Best Play in the Housing Market
- Options Trading – Understanding Strike Price
- 2 Energy Stocks Fueling the AI Datacenter Boom
- What is the Nikkei 225 index?
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Altamira Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altamira Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
